Biotech RadarJobs updated

COMPANY

Travera

HQ: Medford, MA source · travera.com ↗

Keywords: oncology cancer Malignant Pleural Effusion Malignant Ascites Hepatocellular Carcinoma Renal Cell Carcinoma Non-Small-Cell Lung Carcinoma Neuroendocrine Carcinoma Thymic Carcinoma Pancreatic Carcinoma Carcinoma Breast Ovarian Carcinoma Carcinoma Bladder Carcinoma of Unknown Primary Carcinoma of the Head and Neck Carcinoma of the Oropharynx Carcinoma of the Larynx Carcinoma of Esophagus Carcinoma of the Penis Carcinoma of the Anus Carcinoma of the Vulva Carcinoma of the Appendix Carcinoma of the Oral Cavity Cholangiocarcinoma Mesothelioma Multiple Myeloma in Relapse Renal Carcinoma Small Cell Carcinoma Pancreatic Ductal Carcinoma Carcinoma of the Bladder Carcinoma of the Nasopharynx Carcinoma of the Cervix Melanoma Pancreatic Cancer Stage III Breast Cancer Stage IV Breast Cancer Stage III Lung Cancer Stage IV Lung Cancer AML Carcinoma of Lung Carcinoma Prostate

Location: Medford, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start —: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs source ↗
  2. Trial start —: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) source ↗
  3. Trial start —: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT05461430Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)Not listedCompletedJul 15, 2022Mar 23, 2026 (actual)
NCT04985357Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsNot listedWithdrawn2024-112028-05 (estimated)
NCT03777410Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple MyelomaNot listedTerminatedFeb 11, 2019Jun 30, 2024 (actual)
Feedback